SCHEMBL18530398

SCHEMBL18530398

CC(NC(=O)OC(C)(C)C)c1ccc(N2CCN(C(=O)CCOCC(=O)O)CC2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 9/20 0.41
▸ NPC1 O15118 3/20 0.41
▸ GAA P10253 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.39
▸ LMNA P02545 2/20 0.39
▸ SMN1; SMN2 Q16637 4/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ ATM Q13315 1/20 0.39
▸ CTSK P43235 2/20 0.38
▸ CTSS P25774 1/20 0.38
▸ NPSR1 Q6W5P4 3/20 0.38
▸ HTT P42858 2/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ GFER P55789 1/20 0.38
▸ SIGMAR1 Q99720 1/20 0.38
▸ FOLH1 Q04609 1/20 0.38
▸ POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18530448 1.00 MAPT (0.41) MAPTNPC1GAAKDM4EALDH1A1
SCHEMBL18611924 0.87 GRM5 (0.44) MAPTNPC1GAAKDM4EMEN1
SCHEMBL18551120 0.87 ME2 (0.43) MAPTNPC1GAAKDM4ELMNA
SCHEMBL18591875 0.82 MAPT (0.49) MAPTNPC1GAAKDM4EALDH1A1
SCHEMBL18530433 0.81 SIGMAR1 (0.52) MAPTNPC1GAAKDM4EALDH1A1
SCHEMBL18551128 0.79 LRRK2 (0.43) —
SCHEMBL21378568 0.78 HDAC3 (0.43) MAPTNPC1GAAALDH1A1LMNA
SCHEMBL21378571 0.78 HDAC3 (0.43) MAPTNPC1GAAALDH1A1LMNA
SCHEMBL29067298 0.78 PHGDH (0.47) MAPTGAAKDM4EALDH1A1MEN1
SCHEMBL18551119 0.77 ACACB (0.42) MAPTALDH1A1LMNASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250228944-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS ARVINAS OPERATIONS, INC. 2025-07-17 — — US disclosed
US-12171831-B2 Compounds and methods for the targeted degradation of bromodomain- containing proteins ARVINAS OPERATIONS, INC. (US) 2024-12-24 — — US disclosed
US-20230263893-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS ARVINAS OPERATIONS, INC. 2023-08-24 — — US disclosed
US-11554171-B2 Compounds and methods for the targeted degradation of bromodomain-containing proteins ARVINAS OPERATIONS, INC. (US) 2023-01-17 — — US disclosed
US-20210187108-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS ARVINAS OPERATIONS, INC. 2021-06-24 — — US disclosed
US-10772962-B2 Compounds and methods for the targeted degradation of bromodomain-containing proteins ARVINAS OPERATIONS, INC. (US) 2020-09-15 — — US disclosed
EP-3337476-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS Arvinas, Inc. (US) 2018-06-27 — — EP disclosed
US-20170065719-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS ARVINAS OPERATIONS, INC. 2017-03-09 — — US disclosed
WO-2017030814-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS Arvinas, Inc. (US) 2017-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10772962-B2 Compounds and methods for the targeted degradation of bromodomain-containing proteins BRPF3, STUB1, BRDT MAPT 2849/4885NPC1 2682/4885GAA 1277/4885
US-11554171-B2 Compounds and methods for the targeted degradation of bromodomain-containing proteins BRPF3, STUB1, BRDT MAPT 2849/4885NPC1 2682/4885GAA 1277/4885
US-20210187108-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS BRPF3, STUB1, BRDT MAPT 2849/4885NPC1 2682/4885GAA 1277/4885
US-12171831-B2 Compounds and methods for the targeted degradation of bromodomain- containing proteins BRPF3, STUB1, BRDT MAPT 2849/4885NPC1 2682/4885GAA 1277/4885
US-20230263893-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS BRPF3, STUB1, BRDT MAPT 2849/4885NPC1 2682/4885GAA 1277/4885
US-20250228944-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS BRPF3, STUB1, BRDT MAPT 2849/4885NPC1 2682/4885GAA 1277/4885
US-20170065719-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS BRPF3, STUB1, BRDT MAPT 2849/4885NPC1 2682/4885GAA 1277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback